ema bpc 157 status BPC-157 Explained: Benefits, Safety & Oral vs Injectable Options What is BPC-157? | Everything
Description
Tirzepatide + BPC-157 contains: Tirzepatide (Dual GIP/GLP-1 Agonist), BPC-157 (Body Protection Compound)
Binding affinity occurs at nanomolar levels
Mechanistically, ALM activates retinoid X receptor- (RXR) through stable hydrogen bond formation, thereby upregulating caudal-type homeobox transcription factor 2 (CDX2) and cystic fibrosis transmembrane conductance regulator (CFTR), while concurrently suppressing -catenin/Snail-mediated epithelial-mesenchymal transition (EMT)
Moreover, the peptide has been tested in intranasal doses of up to 15mg, with researchers suggesting favorable safety and effectiveness when administered no more than twice weekly for 12 weeks [11]
